Siaton, Evamie M.
HRN: 21-97-76 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/26/2023
CO-AMOXICLAV 625MG (TAB)
02/26/2023
03/05/2023
PO
500mg
Q12
S/P NSVD With Repair
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes